Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Study summary

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedYL201 and Tarlatamab

Plus 1 other study approaches.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 20, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?36 U.S. locations

Locations may change over time.

Who runs it?Amgen

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Amgen
Interventions being studied: Drug: YL201; Drug: Tarlatamab; Drug: Durvalumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Small cell lung cancer (SCLC)→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participants ≥ 18 years of age (or legal adult age within country) at time of signing informed consent.
Participants with histologically or cytologically confirmed ES-SCLC.
For Parts 1 and 2, subjects must have ES-SCLC that has progressed or recurred following at least 1 prior line of platinum-based anti-cancer therapy received either for LS-SCLC or ES-SCLC.
For Part 3, subjects must have ES-SCLC and no prior systemic treatment for ES SCLC other than 1 cycle of platinum-based chemotherapy, and etoposide, and with or without PD-(L)1 inhibitor in the first-line setting.
At least 1 measurable lesion as defined by RECIST 1.1.
Participants must have adequate organ function (cardiac, pulmonary, kidney, bone marrow, and liver).

Reasons someone may not be able to joinExclusion criteria

Prior delta-like ligand 3 (DLL3) or B7 homolog 3 (B7-H3) targeted therapy.
Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.
Symptomatic central nervous system (CNS) metastases. Note: Participants with asymptomatic brain metastases are eligible as defined in the protocol.
History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
Baseline requirement of supplemental oxygen.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

City of Hope Orange County Lennar Foundation Cancer CenterIrvine, California
Yale New Haven HospitalNew Haven, Connecticut
Moffitt Cancer CenterTampa, Florida
Dana Farber Cancer InstituteBoston, Massachusetts
Siteman Cancer CenterSt Louis, Missouri
Sanford Roger Maris Cancer CenterFargo, North Dakota
Cleveland Clinic FoundationCleveland, Ohio
Sanford Oncology Clinic and PharmacySioux Falls, South Dakota
University of Texas MD Anderson Cancer CenterHouston, Texas
Swedish Medical CenterSeattle, Washington
Fred Hutchinson Cancer CenterSeattle, Washington
CHU de Quebec Hopital de l Enfant JesusQuébec, Quebec

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2026. Always confirm current availability with the study team.

View original record ↗